Oncology API impurity and reference standards
Impurities, degradants and reference standards for cytotoxic and targeted oncology APIs — supporting potency assays, related-substances control and nitrosamine risk assessment in high-potency handling environments.
HPAPI
handling tier
Related
substances focus
NDSRI
risk assessed
CRM / WS
grades
ICH
Q3A/Q3B
Oncology chemistry and impurity control
Oncology small molecules often combine reactive functional groups (alkylators, kinase hinges) with strict related-substance limits because degradants may retain pharmacological or toxicological activity.
High-potency containment affects how standards are packaged and shipped; COA and SDS reflect occupational exposure bands appropriate to the structure class.
Standard categories
Process impurities
- Unreacted intermediates from heterocyclic coupling
- Regioisomers from selective substitution routes
Degradants
- Hydrolysis and oxidation products in stable form
- Dimer or adduct peaks from reactive APIs
Compendial alignment
- Materials supporting USP/EP monograph system suitability
- In-house primary standards qualified against CRM
Indicative supply and handling posture
| Potency band | Packaging | Analytical package |
|---|---|---|
| Standard oral API | Glass or HDPE, standard ship | COA + SDS |
| HPAPI (OEL band controlled) | Double containment, split mg aliquots | Added potency verification |
| Nitrosamine-risk oncology route | Separate from nitrosating reagents in lab | Optional NDSRI standard bundle |
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Typical COA for oncology impurity standards
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Identity
HRMS + NMR
Structure class verified
Purity
≥95–98%
Method stated
Related substances
Reported
Critical pairs identified
Potency assay
When API-like activity relevant
Project-specific
Residual solvents / metals
As per spec
Catalyst routes
Figures are indicative industry-typical values. Lot- and project-specific data appear on the quotation and certificate of analysis.
Deliverables
- Oncology impurity standard with lot control
- HPAPI handling instructions where applicable
- Linkage to nitrosamine and isotope standards for same API
- Custom synthesis for programme-specific degradants
- Quote cross-reference to oncology small-molecule catalogue
Frequently asked questions
Some structures require ADR/IATA classification. SDS and ship mode are confirmed at quote.
Related
Nitrosamine Impurities
Small-molecule nitrosamines and nitrosamine drug substance-related impurities (NDSRIs) as reference materials for confirmatory testing, CPCA categorization and acceptable intake (AI) justification under current FDA, EMA and ICH M7 expectations.
View detailsCertified Reference Materials
Impurities and API-related CRMs with certified property values, measurement uncertainty and metrological traceability — produced or distributed under principles aligned with ISO 17034 for method validation and lab accreditation.
View detailsWorking Standards
Secondary working standards traceable to primary or certified reference materials — qualified under ISO/IEC 17025-style laboratory practice for daily HPLC, GC and titre use without consuming CRM inventory.
View detailsCustom Impurity Synthesis
When catalogue search does not return your peak, we design a synthesis or isolation route for deletion peptides, genotoxic alerts, nitrosamines, metabolites and chiral variants — with a documented package for qualification.
View detailsReady to specify this for your program?
Share sequence, scale and documentation needs. We reply with indicative specs and a project-specific quotation.